The allure of high-tech cardiac imaging has proved strong enough to entice venture capitalists to invest $21 million in NexRay, developers of a low-dose x-ray fluoroscopy system. The fledgling product, which uses a proprietary technology called
The allure of high-tech cardiac imaging has proved strong enough to entice venture capitalists to invest $21 million in NexRay, developers of a low-dose x-ray fluoroscopy system. The fledgling product, which uses a proprietary technology called Scanning-Beam Digital X-ray, promises to deliver 3-D imaging applicable to the interventional cardiology market. NexRay, formerly Cardiac Mariners, promises improved image quality and up to 90% reduction in radiation exposure to the patient and staff.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
AI-Initiated Recalls After Screening Mammography Demonstrate Higher PPV for Breast Cancer
March 18th 2025While recalls initiated by one of two reviewing radiologists after screening mammography were nearly 10 percent higher than recalls initiated by an AI software, the AI-initiated recalls had an 85 percent higher positive predictive value for breast cancer, according to a new study.
Study: Monitoring of Prostate MRI Exams Could Lead to 75 Percent Reduction of Gadolinium Contrast
March 17th 2025While DCE MRI was deemed helpful in over 67 percent of cases in which it was used, researchers found that monitored prostate MRI exams, which facilitated a 75 percent reduction of DCE MRI sequences, had comparable sensitivity for prostate cancer as non-monitored exams.